Galiz Research | Hialeah, FL

Research site

(Unclaimed)

Location

7100 W 20th Avenue, 802, Hialeah, Florida, United States of America

Site insights

Top conditions

Top treatments

KarXT

Troriluzole

Brexpiprazole

SEP-363856

Simufilam

Risperidone

Glucose

Aticaprant

Cannabidiol

Trospium Chloride

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 52 total trials

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), includ...

Enrolling

SM With an Associated Hematologic Neoplasm (SM-AHN)

Aggressive Systemic Mastocytosis (ASM)

Drug: bezuclastinib

[18F]PI-2620 Phase 3 Histopathological Study

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620...

Enrolling

Alzheimer Disease

Drug: [18F]PI-2620

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in ba...

Enrolling

Treatment Resistant Depression

Device: Vagus Nerve Stimulation (VNS)

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to...

Enrolling

Alzheimer Disease

Drug: Zunveyl®

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female...

Enrolling

Psychosis Associated With Alzheimer's Disease

Drug: KarXT

Drug: Placebo

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

Enrolling

Schizophrenia

Drug: SEP-363856

Other: Placebo

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN0...

Enrolling

Psychosis Associated With Alzheimer's Disease

Drug: KarXT